Spyre Therapeutics, Inc.
NASDAQ:SYREBiotechnology
Healthcare
$97.63 +1.38%
+$1.21 today
- Market cap
- $9.27B
- Beta
- 3.06
- P/E (TTM)
- -171.1
- EPS (TTM)
- -$0.52
52W Low $14.00High $91.04
Volume 0.63M
Average 1.17M
Balance Sheet
Inspect the capital base behind the business.
Assets
$777.78M
FY 2025 · Annual
+27.8% YoYLiabilities
$62.55M
FY 2025 · Annual
-31.0% YoYEquity
$715.24M
FY 2025 · Annual
+38.1% YoYBalance Sheet
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 15.14M | 34.86M | 188.89M | 89.42M | 85.72M |
| Short-term Investments | 77.99M | 20.85M | 150.38M | 513.67M | 670.81M |
| Net Receivables | 815K | 375K | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 6.17M | 2.25M | 5.39M | 21.25M |
| Total Current Assets | 98.89M | 62.26M | 341.53M | 608.47M | 777.78M |
| Property, Plant & Equipment (Net) | 8.36M | 6.65M | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 2.68M | 2.24M | 331K | 10K | 0 |
| Total Non-current Assets | 11.04M | 8.89M | 331K | 10K | 0 |
| Total Assets | 109.93M | 71.14M | 341.86M | 608.48M | 777.78M |
| Account Payables | 3.32M | 677K | 896K | 666K | 8.9M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 2.36M | 517K | 0 | 0 | 0 |
| Other Current Liabilities | 4.99M | 4.92M | 5.93M | 31.27M | 30.94M |
| Total Current Liabilities | 20.14M | 14.66M | 31.98M | 54.06M | 58.69M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 1.22M | 2.18M | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 125.87M | 36.62M | 3.86M |
| Total Non-current Liabilities | 5.84M | 6.18M | 125.87M | 36.62M | 3.86M |
| Total Liabilities | 25.99M | 20.84M | 157.84M | 90.68M | 62.55M |
| Common Stock | 5K | 6K | 10K | 13K | 15K |
| Retained Earnings | (341.81M) | (425.62M) | (764.41M) | (972.43M) | (1.13B) |
| Accumulated OCI | (20K) | (48K) | 302K | 180K | 869K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 83.94M | 50.31M | 184.02M | 517.8M | 715.24M |
| Total Debt | 5.06M | 4.63M | 0 | 0 | 0 |
| Net Debt | (10.08M) | (30.23M) | (188.89M) | (89.42M) | (85.72M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $82.7M |
| Short-term Investments | $989.2M |
| Other Current | $27.8M |
| Total Current Assets | $1.1B |
| Total Assets | $1.1B |
Analysis
Selected assets total $1.1B for Latest. The largest visible component is Short-term Investments at $989.2M, about 89.9% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 3, 2026 | |
| 8-K | Current report | Nov 3, 2026 | |
| SC 13D/A | SC 13D/A filing | Oct 9, 2026 | |
| 8-K | Current report | Oct 7, 2026 | |
| 424B5 | 424B5 filing | Oct 6, 2026 |
How much cash does SYRE have?
Spyre Therapeutics, Inc. (SYRE) reported $85.72M in cash and equivalents in fiscal 2025.
How much debt does SYRE carry?
Spyre Therapeutics, Inc. (SYRE) reported $0.00 of total debt, with net debt of -$85.72M.
Continue the stock analysis
Jump to another research area for this company.